Holen Sie sich die Stockscreener-App
0.2901
0.12%
-0.0002
Schlusskurs vom Vortag:
$0.2899
Offen:
$0.295
24-Stunden-Volumen:
198.64K
Relative Volume:
0.31
Marktkapitalisierung:
$29.99M
Einnahmen:
$1.27M
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-5.5575
EPS:
-0.0522
Netto-Cashflow:
$-5.28M
1W Leistung:
-2.15%
1M Leistung:
+12.84%
6M Leistung:
-0.09%
1J Leistung:
-31.06%
1-Tages-Spanne:
$0.2893
$0.296
1-Wochen-Bereich:
$0.2875
$0.3038
52-Wochen-Spanne:
$0.235
$0.4508
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Compare IGC vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.2901 | 29.97M | 1.27M | -7.12M | -5.28M | -0.0522 |
VRTX
Vertex Pharmaceuticals Inc
|
520.68 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.99 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,005.68 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.22 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.66 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
Price to earnings forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer's 2027 Outlook - marketscreener.com
Nasdaq 30's VIVS, IGC, RIME, AIXI Stocks Now - openPR.com
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now - FinancialContent
IGC (IGC) Technicals: Falls 0.65% to $0.31 on the Day; Level Watch: $0.29 and $0.33 Define the Nearby Reference Levels in the Latest ReadingLarge Cap Trends - vinanet.vn
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - openPR.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com India
IGC (IGC) Earnings Data Review: The Bottom-Line Figure Outpaces Its Comparison at the Close; Session Reaction: Shares Move 1.43% Higher in the Current UpdatePost-Earnings Reaction - vinanet.vn
IGC Pharma earnings matched, revenue fell short of estimates - Investing.com
IGC Pharma Releases Q2 2026 Financial Results - AlphaStreet
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - openPR.com
IGC Pharma Q2 Results: Sales up 39% YoY, EPS loss widens to $(0.03) - scanx.trade
IGC Looks 24.1% Overvalued on GF Value™ - GuruFocus
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure - Finviz
IGC Pharma Q2 Results: CALMA Nears Enrollment Closure - accessnewswire.com
IGC Pharma, Inc. 2026: Revenue $265K, EPS ($0.03) — 10-Q Summary - TradingView
IGC Pharma (NYSE: IGC) widens loss while Phase 2 Alzheimer’s trial hits key milestone - Stock Titan
IGC Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build - openPR.com
IGC Pharma (NYSE American:IGC): What Does the Latest Update Mean for Clinical Development? - Kalkine Media
IGC Pharma Inc (IGC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s regulatory execution Update Reveal? - Kalkine Media
IGC Pharma (NYSE AMERICAN:IGC): What Could Today’s cannabinoid research progress Update Reveal? - Kalkine Media
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to WatchPlus More in Focus - openPR.com
Early Alert: PLAG, PRSO, UZX, IGC Lead Sub-$1 Stocks to Watch – Plus More in Focus - FinancialContent
IGC Looks 21.6% Overvalued on GF Value™ - GuruFocus
IGC Pharma Advances CALMA Toward Q4 Topline Readout - ACCESS Newswire
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout - Corsicana Daily Sun
IGC Pharma (IGC) Climbs 5% to $0.28, Testing Key Resistance at $0.29NHNL Divergence - dars.gov.et
IGC Pharma Inc (IGS1.DU) balance sheet - Yahoo Finance UK
Enterprise value to revenue forward of IGC Pharma, Inc. – AMEX:IGC - TradingView
IGC Pharma Inc (IGC) Stock News Today - TradingKey
Price to sales forward of IGC Pharma, Inc. – MUN:IGS1 - TradingView
Bullish Volume: RITR, IGC, BJDX, CISS Lead Active Sub-$1 Stocks to Watch - openpr.com
IGC Pharma Evaluates Recovery After Left Verdict - ACCESS Newswire
IGC Q1 2026 Earnings: Narrower-Than-Expected Loss Marks 14.16% EPS BeatQuarterly Earnings Report - vinanet.vn
Microcaps MGRX, PRSO, IGC, KUST In the News to Watch - openPR.com
IGC Pharma, Inc. Revenue Breakdown – AMEX:IGC - TradingView
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign - The Batesville Daily Guard
IGC|IGC Pharma Inc|Price:0.266|Chg%:+0.002 - TradingKey
IGC Pharma Hovers Near Support as Slight Decline Tests $0.26 LevelRetail Volume - vinanet.vn
IGC|IGC Pharma Inc|Price:0.248|Chg%:-0.001 - TradingKey
IGC Pharma Inc (IGC) Cash Flow - TradingKey
IGC Pharma Inc (IGC) Balance Sheet - TradingKey
IGC Pharma Inc (IGC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IGC Pharma Inc (IGC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IGC Pharma Inc (IGC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IGC Pharma, Inc. Revenue Breakdown – SWB:IGS1 - TradingView
IGC Pharma, Inc. Revenue Breakdown – LS:A1T87A - TradingView
IGC Q1 2026 Earnings: Narrowed Loss Beats Expectations Despite Lack of Revenue DisclosureEPS Estimate Trend - Vinanet
IGC Pharma Inc (IGC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):